Following publication of KEYNOTE-689 Phase 3 results confirming the role of perioperative checkpoint inhibition in head and neck cancer, GeoVax announced plans for a Phase 2 trial (AdPNP-203) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback